HOME >> BIOLOGY >> NEWS
UW-Madison scientists return to rat as biomedical research tool

MADISON - Ever a favorite of biologists because of its record as a model to understand ailments like diabetes and cancer, the lab rat lost its luster as a research tool during the past decade because it defied attempts to manipulate its genome in a prescribed way.

Now, using a novel combination of tried-and-true techniques, scientists have created the first "knockout" rats, specifically rats whose genomes have been stripped of genes that suppress breast cancer. The development, reported today (May 19) by a team of scientists from the University of Wisconsin-Madison in online editions of the journal Nature Biotechnology, promises to restore the rat to biomedical prominence.

"People have tried for more than 10 years to produce a knockout rat," says Michael N. Gould, a professor of oncology at UW-Madison's McArdle Laboratory for Cancer Research and in whose laboratory the work was conducted.

For 100 years, he explains, the rat was the model of choice for many biomedical scientists. But a decade ago, when knockout technology was first widely deployed in the mouse, the sturdy rat was dethroned. Researchers rushed to take advantage of the biomedical possibilities of an animal model whose genome could be manipulated at will, adding or subtracting genes to gain surprising insight into a host of diseases and potential treatments.

The rat, says Gould, had been "compromised by the lack of a full genetic toolbox. Over the last 10 years, the government and drug companies have invested a lot in bringing the rat up to speed. But one of the last major elusive tools for our toolbox was the ability to knock out genes."

The ability to add or subtract genes to an animal's genome lends powerful insight into the basic mechanisms of disease. New methods of disease prevention and treatment in humans, as well as a better basic understanding of development, physiology and pathology have resulted from the ability of scientists to manipulate genes in liv
'"/>

Contact: Michael Gould
gould@oncology.wisc.edu
608-263-6615
University of Wisconsin-Madison
18-May-2003


Page: 1 2 3

Related biology news :

1. UW-Madison scientists find a key to cell division
2. National nanotech expert to address UW-Madison conference
3. UW-Madison researchers identify key to cancer cell mobility
4. UW-Madison team develops technique to create flu viruses
5. DNA lends scientists a hand, revealing new chemical reactions
6. Conference at UH opens doors for new scientists, engineers
7. Wisconsin scientists develop quick botox test
8. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
9. Alaska scientists find Arctic tundra yields surprising carbon loss
10. UAF scientists discover new marine habitat in Alaska
11. Information system to help scientists analyze mechanisms of social behavior

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Madison scientists return rat biomedical research tool

(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... awarded the 44th Rosenstiel Award for Distinguished Work in ... exploring the mechanisms of genomic instability and its implications ... the second alumnus to win the Rosenstiel Award; the ... , Alt is the Charles A. Janeway Professor of ... and an investigator at the Howard Hughes Medical Institute ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
(Date:10/22/2014)... October 21, 2014 The North American ... market North America with analysis and forecast of revenue. ... and is expected to reach $623.6 million by 2018, ... , Browse through the TOC of the North American ... the in-depth analysis provided. This also provides a glimpse ...
(Date:10/22/2014)... Diego, CA (PRWEB) October 22, 2014 ... balances from Sartorius, A & D Weighing, Rice ... Sartorius CPA Semi-Micro Balance . The Sartorius CPA ... for an affordable high-quality, precise, and user-friendly laboratory ... manufacturing of laboratory equipment, their laboratory balances are ...
(Date:10/22/2014)... --  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... and diseases, announced today that the U.S. Patent and ... a composition of matter patent application that covers the ... This is Synthetic Biologics, first allowed patent application directly ... the Company,s extensive C. difficile patent estate. ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
Cached News: